Orlance

Orlance, based in Seattle, Washington, is actively advancing its MACH-1® platform with the goal of delivering nucleic acid vaccines and related treatments without the limitations of cold chain requirements. The company has utilized $9.6 million in NIH SBIR funding to progress the MACH-1 platform, which allows for the intradermal delivery of stable, powdered vaccines in a needle-free manner. Through the use of innovative technology, Orlance aims to address logistical obstacles associated with vaccine distribution and administration, thereby contributing to enhanced accessibility and effectiveness in the realm of nucleic acid vaccines.